Sugi Predict

Sugi Predict / Targets / NAALAD2

NAALAD2

N-acetylated-alpha-linked acidic dipeptidase 2 · Q9Y3Q0 · NAALAD2 on Sugi Atlas →

19,669 patent compounds predicted against NAALAD2, 11,741 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL148582 SCHEMBL148582 0.75 7/20
SCHEMBL148583 SCHEMBL148583 0.75 7/20
SCHEMBL60370 SCHEMBL60370 0.55 6/20
SCHEMBL60371 SCHEMBL60371 0.55 6/20
Carglumic Acid Carglumic Acid (SCHEMBL373546) 0.69 5/20
Carglumic Acid Carglumic Acid (SCHEMBL910483) 0.69 5/20
Carglumic Acid Carglumic Acid (SCHEMBL910527) 0.69 5/20
SCHEMBL910174 SCHEMBL910174 0.64 5/20
SCHEMBL910175 SCHEMBL910175 0.64 5/20
SCHEMBL910273 SCHEMBL910273 0.64 5/20
SCHEMBL910360 SCHEMBL910360 0.64 5/20
SCHEMBL73336 SCHEMBL73336 0.63 5/20
SCHEMBL910469 SCHEMBL910469 0.63 5/20
SCHEMBL911011 SCHEMBL911011 0.63 5/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL910549) 0.62 5/20
SCHEMBL910607 SCHEMBL910607 0.62 5/20
SCHEMBL869873 SCHEMBL869873 0.60 5/20
Oxalic Acid Oxalic Acid (SCHEMBL910834) 0.60 5/20
Succinic Acid Succinic Acid (SCHEMBL911170) 0.60 5/20
Maleic Acid Maleic Acid (SCHEMBL910784) 0.55 5/20

Clinical trials — most relevant to NAALAD2 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
A Safety and Efficacy Study of Fabrazyme® Replacement Therapy in Patients With Cardiac Fabry Disease PHASE4COMPLETED
Acid Lipase Replacement Investigating Safety and Efficacy (ARISE) in Participants With Lysosomal Acid Lipase Deficiency PHASE3COMPLETED
Acelarin First Line Randomised Pancreatic Study PHASE2/PHASE3SUSPENDED
18F-DCFPyL PET/CT in High Risk and Recurrent Prostate Cancer PHASE2ACTIVE_NOT_RECRUITING
Pegaspargase and Methotrexate Based Regimens for Newly Diagnosed Extranodal NK/T Cell Lymphoma PHASE2COMPLETED
A Treatment Study of Mucopolysaccharidosis Type IIIB PHASE1/PHASE2COMPLETED
A Study of the Tolerance, Safety, and Pharmacokinetics of GNR-055 in Healthy Volunteers PHASE1COMPLETED
Acute Pancreatitis Targets (APT) Study nanCOMPLETED
Biomarker for Mucolipidosis Disorder Type I, II, III, IV (BioML) nanWITHDRAWN
Lysine Oxidation in Response to Arginine Supplementation nanCOMPLETED
The Natural History of Alpha-Mannosidosis nanCOMPLETED
Genetic Studies of Lysosomal Storage Disorders nanENROLLING_BY_INVITATION
A Prospective Natural History Study of Mucopolysaccharidosis Type IIIB (MPS IIIB) nanUNKNOWN
SRT in Comparison to ERT on Immune Aspects and Bone Involvement in Gaucher Disease nanUNKNOWN
Ovarian Reserve and Matrix Metalloproteinases nanCOMPLETED
Using Next-generation Sequencing in the Diagnosis of Epilepsy and/or Intellectual Disability in a Pediatric Cohorte nanCOMPLETED
Screening of Lysosomal Storage Disorders Diseases in Minority Groups nanUNKNOWN
Pharmacokinetics of Low Molecular Weight Heparin in Cancer Patients nanCOMPLETED
A Multicenter Selective Screening Study to Investigate the Frequency of Neuronal Ceroid Lipofuxinosis Type 2 (CLN2) nanRECRUITING
The Natural History of Sialidosis Type I nanRECRUITING
Genome Environment Microbiome and Metabolome in Autism Study nanCOMPLETED
Integrated Proteomic HPLC-ESI-MS Analysis of Salivary Peptides of Preterm Newborns: a Pilot Study nanCOMPLETED
Identification of Undiagnosed Lysosomal Acid Lipase Deficiency nanUNKNOWN
Plasma Molecular Profiling in ALK Inhibitor Resistant NSCLC nanCOMPLETED
Efficacy of a Rinse Containing Sea Salt and Lysozyme on Biofilm and Gingival Health nanCOMPLETED
Respiratory Cathepsins, Proteases Inhibitors and Glycosaminoglycans (GAG) in Mucopolysaccharidosis nanCOMPLETED
Registry Gangliosidoses nanUNKNOWN
Effect of Arginine and Glutamine on Radiation-induced Oral Mucositis: a Trible Blinded Randomized Controlled Clinical Trial nanCOMPLETED
Biomarker for Hurler Disease (BioHurler) nanWITHDRAWN
Diffusion Tensor Imaging (DTI) in Infants With Krabbe Disease nanACTIVE_NOT_RECRUITING

Related proteins — ESM-2 sequence neighbours (a NAALAD2 binder may also engage these)

ProteinNameSimilarity
Q9CZR2 — 1.000 Q9CZR2 →
FOLH1 Glutamate carboxypeptidase 2 0.997 landscape →
O77564 — 0.997 O77564 →
O35409 — 0.997 O35409 →
Q9HBA9 — 0.995 Q9HBA9 →
P70627 — 0.994 P70627 →
Q17QK3 — 0.972 Q17QK3 →
Q5RDN7 — 0.972 Q5RDN7 →
Q9Y646 — 0.969 Q9Y646 →
Q6IRK9 — 0.968 Q6IRK9 →
Q9WVJ3 — 0.967 Q9WVJ3 →
Q6GQ29 — 0.962 Q6GQ29 →
Q9R1E6 — 0.953 Q9R1E6 →
Q4R854 — 0.953 Q4R854 →
F8S0Z7 — 0.952 F8S0Z7 →
Q9QX15 — 0.952 Q9QX15 →
Q05927 — 0.952 Q05927 →
ENPP2 Autotaxin 0.951 landscape →
P21588 — 0.951 P21588 →
P78562 — 0.950 P78562 →
B6EWW8 — 0.950 B6EWW8 →
Q64610 — 0.950 Q64610 →
Q9D379 — 0.949 Q9D379 →
Q5M854 — 0.949 Q5M854 →
O77836 — 0.949 O77836 →
P08430 — 0.949 P08430 →
Q8R455 — 0.949 Q8R455 →
ENPP1 Ectonucleotide pyrophosphatase/phosphodiesterase family member 1 0.948 landscape →
NT5E 5'-nucleotidase 0.948 landscape →
Q5REP8 — 0.948 Q5REP8 →